Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma
Table 4
Clinicopathological characteristics of 547 EC patients in TCGA.
Characteristics
Vimentin negative
Vimentin positive
value
Age (years)
64 (31-90)
67 (33-90)
61 (31-89)
<0.001
FIGO stage
<0.001
I
342
152 (55.27%)
190 (69.85%)
II
52
28 (10.18%)
24 (8.82%)
III
123
70 (25.45%)
53 (19.49%)
IV
30
25 (9.09%)
5 (1.84%)
Menopause
<0.001
Premenopause
35
6 (2.36%)
29 (11.03%)
Perimenopause
17
8 (3.15%)
9 (3.42%)
Postmenopause
448
234 (92.13%)
214 (81.37%)
Indeterminate
17
6 (2.36%)
11 (4.18%)
BMI (kg/m2)
0.262
<18.5
5
3 (1.16%)
2 (0.72%)
18.5-24.9
110
53 (20.54%)
57 (20.43%)
25.0-29.9
115
57 (22.09%)
58 (20.79%)
≥30
307
145 (56.20%)
162 (58.06%)
NA
30
Histologic grade
<0.001
1
99
27 (9.82%)
72 (26.47%)
2
122
38 (13.82%)
84 (30.88%)
3
315
199 (72.36%)
116 (42.65%)
High grade
11
11 (4.00%)
0 (0.00%)
Residual tumor
0.059
R0
376
181 (79.39%)
195 (85.90%)
R1
22
15 (6.58%)
7 (3.08%)
R2
16
12 (5.26%)
4 (1.76%)
RX
41
20 (8.77%)
21 (9.25%)
NA
92
Histological type
0.002
I
410
160 (58.18%)
250 (91.91%)
II
137
115 (41.82%)
22 (8.09%)
Vital state
0.047
Alive
502
246 (89.45%)
256 (94.12%)
Dead
45
29 (10.55%)
16 (5.88%)
EC: endometrial carcinoma; TCGA: The Cancer Genome Atlas; FIGO: Federation International of Gynecology and Obstetrics Association; BMI: body mass index; NA: NA means that the data is not available; RX: RX meant residual tumor in stages more than 2. The ages in the table are in years and are shown as medians and ranges.
